Working Life: Maneesh Juneja
pharmafile | April 3, 2009 | Feature | Research and Development |Â Â GSK, productivityÂ
How did you find your way into your current role?
After graduating with a degree in business & computing, I began my career as a junior analyst at University College London within epidemiology and public health. This was my first encounter with the statistical software, SAS. I subsequently decided to explore the world of commerce, and worked as a marketing analyst within the field of CRM/direct marketing, mainly for banking and retail clients.
After five years of marketing analysis, I wanted a role that was more socially rewarding. When the opportunity came up within Worldwide Epidemiology at GlaxoSmithKline, I grabbed it with both hands.
I'm fortunate that I've found an area of GSK that allows me to merge my commercial analysis skills with my experience of epidemiology. I've been able to take my 'toolkit' of SAS analysis skills that I developed with large transactional customer databases, and apply it to anonymised patient level data. I've been doing this for six years now, and I can use my experience to create innovative data driven solutions with business benefit that can be applied across the entire drug development lifecycle. I work in a team of analysts, across all therapeutic areas.
Click here to read the article in full on InPharm.com.
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …






